Corcept Therapeutics (NASDAQ:CORT) Issues Quarterly Earnings Results

Posted by Stanley Muller on Jul 29th, 2026

Corcept Therapeutics (NASDAQ:CORT – Get Free Report) posted its earnings results on Wednesday. The biotechnology company reported $0.36 earnings per share for the quarter, topping the consensus estimate of $0.02 by $0.34, FiscalAI reports. Corcept Therapeutics had a return on equity of 7.40% and a net margin of 6.14%.The firm had revenue of $256.15 million for the quarter, compared to analyst estimates of $221.15 million.

Corcept Therapeutics Stock Down 1.3%

Shares of NASDAQ:CORT traded down $1.24 during mid-day trading on Wednesday, reaching $92.95. 1,507,506 shares of the stock were exchanged, compared to its average volume of 1,582,470. The stock’s 50 day simple moving average is $81.83 and its 200-day simple moving average is $55.40. Corcept Therapeutics has a one year low of $28.66 and a one year high of $97.63. The company has a market cap of $9.98 billion, a P/E ratio of 265.58 and a beta of 0.47.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on CORT. Wolfe Research lowered Corcept Therapeutics from a “peer perform” rating to an “underperform” rating and set a $50.00 price target on the stock. in a research report on Monday. Zacks Research upgraded Corcept Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, May 4th. Canaccord Genuity Group increased their target price on Corcept Therapeutics from $135.00 to $150.00 and gave the stock a “buy” rating in a research note on Wednesday. HC Wainwright lifted their price target on shares of Corcept Therapeutics from $75.00 to $95.00 and gave the company a “buy” rating in a research note on Tuesday, June 2nd. Finally, Truist Financial upgraded shares of Corcept Therapeutics to a “strong-buy” rating in a report on Monday, June 15th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $94.67.

Get Our Latest Report on CORT

Insider Transactions at Corcept Therapeutics

In other Corcept Therapeutics news, Director James N. Wilson sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, June 16th. The stock was sold at an average price of $83.20, for a total transaction of $832,000.00. Following the completion of the transaction, the director owned 1,094,543 shares of the company’s stock, valued at $91,065,977.60. This represents a 0.91% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Atabak Mokari sold 40,000 shares of Corcept Therapeutics stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $81.15, for a total transaction of $3,246,000.00. Following the completion of the sale, the chief financial officer owned 16,130 shares in the company, valued at $1,308,949.50. This trade represents a 71.26% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 300,000 shares of company stock worth $22,088,050. Corporate insiders own 20.70% of the company’s stock.

Institutional Investors Weigh In On Corcept Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. State Street Corp boosted its stake in shares of Corcept Therapeutics by 0.5% during the 4th quarter. State Street Corp now owns 2,986,056 shares of the biotechnology company’s stock worth $103,915,000 after buying an additional 15,656 shares during the last quarter. Morgan Stanley grew its holdings in shares of Corcept Therapeutics by 34.1% in the 4th quarter. Morgan Stanley now owns 1,592,059 shares of the biotechnology company’s stock valued at $55,404,000 after acquiring an additional 405,081 shares in the last quarter. AQR Capital Management LLC increased its position in shares of Corcept Therapeutics by 546.9% in the third quarter. AQR Capital Management LLC now owns 1,507,209 shares of the biotechnology company’s stock valued at $125,264,000 after acquiring an additional 1,274,215 shares during the last quarter. Epoch Investment Partners Inc. raised its holdings in Corcept Therapeutics by 10.7% during the third quarter. Epoch Investment Partners Inc. now owns 847,104 shares of the biotechnology company’s stock worth $70,403,000 after acquiring an additional 81,700 shares in the last quarter. Finally, Invesco Ltd. raised its holdings in Corcept Therapeutics by 11.5% during the fourth quarter. Invesco Ltd. now owns 816,996 shares of the biotechnology company’s stock worth $28,431,000 after acquiring an additional 84,413 shares in the last quarter. 93.61% of the stock is currently owned by institutional investors and hedge funds.

About Corcept Therapeutics

(Get Free Report)

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.